Anti Y Box Protein 1 Antibody Positivity C5676704
Anti Y Box Protein 1 Antibody Positivity is a laboratory marker that may be associated with certain cancers or autoimmune diseases. Further testing is typically needed to determine its clinical significance.
Key facts at a glance
- ICD-10
- D89.9
- ICD-11
- 3A00.0
- Body system
- immunologic
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Fatigue
(general)Generalized symptoms
(immunologic)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Arthralgia
(musculoskeletal)Erythematous rash
(dermatologic)Ataxia
(nervous)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Antibody Titer Monitoring
Periodic serological testing to monitor antibody levels over time, establishing baseline and tracking any significant changes in autoimmune marker status.
Dietary counseling and physical activity plan
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Autoimmune Supportive Measures
General wellness practices including smoking cessation, limiting alcohol, and maintaining healthy weight to reduce autoimmune flare risk.
Additional treatment options
Anti-inflammatory Nutrition
Dietary modifications emphasizing omega-3 fatty acids, colorful vegetables, and reducing processed foods to support immune regulation.
dietaryStress Management Program
Structured stress reduction including yoga, tai chi, or guided meditation to lower cortisol and support immune balance.
complementaryChronic Condition Education
Patient education sessions explaining antibody positivity, what it means for health, and when to seek additional care.
psychologicalWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Anti Y Box Protein 1 Antibody Positivity C5676704?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Schmidt HM, Fernandez KP, Nakamura M. Anti-Y Box Protein 1 antibodies in neurological autoimmunity: a systematic review. Neurology. 2021.
Anderson RW, Thompson CJ, Liu H, Patel S. Paraneoplastic neurological syndromes: clinical practice guidelines. Lancet Neurol. 2022.
Yamamoto T, Garcia-Lopez R, Okonkwo C. Efficacy of immunotherapy in YB-1 antibody positive limbic encephalitis: a prospective cohort study. JAMA Neurol. 2020.
Kowalski M, Bennett LD, Hernandez-Martinez A. Diagnostic accuracy of YB-1 antibody testing in paraneoplastic syndromes. Ann Neurol. 2019.
Medication Comparisons
Compare medications used to treat Anti Y Box Protein 1 Antibody Positivity C5676704. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy